Pros and Cons of Ellipsoid Zone as a Surrogate Efficacy Endpoint in Clinical Trials

被引：0
|
作者：
Kuppermann, Baruch D. [1 ]
Singer, Michael A. [2 ]
Sing, Rishi P. [3 ]
机构：
[1] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA
[2] Univ Texas Hlth Sci Ctr, San Antonio, TX USA
[3] Cleveland Clin Martin Hlth, Cleveland Clin, Lerner Coll Med, Stuart, FL USA
来源：
OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2024年 / 55卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] The pros and cons of clinical trials
    Eden, OB
    MEDICAL AND PEDIATRIC ONCOLOGY, 1998, 31 (06): : 521 - 521
  • [2] Pros and cons of pragmatic clinical trials
    Lurie, Jon D.
    Morgan, Tamara S.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2013, 2 (01) : 53 - 58
  • [3] Pros and cons of permutation tests in clinical trials
    Berger, VW
    STATISTICS IN MEDICINE, 2000, 19 (10) : 1319 - 1328
  • [4] Pros and cons of the controlled clinical trials registry
    de León, SP
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2005, 57 (04): : 496 - 497
  • [5] PULMONARY EXACERBATION AS A CLINICAL TRIAL ENDPOINT IN YOUNG CHILDREN: THE PROS & CONS
    Rosenfeld, Margaret
    PEDIATRIC PULMONOLOGY, 2012, 47 : 216 - 217
  • [6] Adaptive clinical trials in sepsis research: pros and cons
    Kesselmeier, M.
    Scherag, A.
    INFECTION, 2019, 47 : S45 - S46
  • [7] Weighing the pros and cons for composite outcomes in clinical trials
    Freemantle, Nick
    Calvert, Melanie
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2007, 60 (07) : 658 - 659
  • [8] Pros and Cons of Noninferiority Trials
    Ofori, Sandra
    Tornberg, Sara V.
    Kilpelainen, Tuomas P.
    Tikkinen, Kari A. O.
    Guyatt, Gordon H.
    Witte, Lambertus P. W.
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 711 - 714
  • [9] PROS AND CONS OF JURY TRIALS
    JANATA, R
    FORUM-AMERICAN BAR ASSOCIATION, 1976, 11 (02): : 590 - 599
  • [10] The pros and cons of noninferiority trials
    Pocock, SJ
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (04) : 483 - 490
12345